Management of Community Program for Opioid Pharmacotherapy (CPOP) patients in a hospital setting

Applicable to: All health professionals handling medicines in WA Health and authorised under the Poisons Regulations 1965 to obtain or possess Schedule 8 medicines

OD 0598/15 will be superseded by MP 0139/20 Medicines Handling Policy on 01 December 2020. OD 0598/15 will remain in effect until this time. For further information, please contact the Medicines and Poisons Regulation Branch MPRB@health.wa.gov.au

Description: This Operational Directive outlines the protocol to be followed when a patient participating in the Community Program for Opioid Pharmacotherapy (CPOP) who is receiving opioid pharmacotherapy is admitted to hospital.

Legal requirements: This Operational Directive outlines the additional requirements to be followed over and above the controls required for other Schedule 8 medicines as outlined in the Western Australian Poisons Regulations 1965

Management of Community Program for Opioid Pharmacotherapy (CPOP) patients in a hospital setting.

The Community Program for Opioid Pharmacotherapy (CPOP) in Western Australia provides pharmacotherapy treatment for opioid dependence, through community based authorised opioid pharmacotherapy prescribers and public prescribers at Next Step Drug and Alcohol Services.

Opioid pharmacotherapies currently include methadone syrup and solution, buprenorphine sublingual tablets as Subutex® and buprenorphine with naloxone sublingual film as Suboxone®. They are supplied through authorised community pharmacies and at Next Step Drug and Alcohol Services to patients following assessment by an authorised CPOP prescriber.

Commencement in CPOP must be by an authorised CPOP prescriber and requires prior authorisation from the Chief Executive Officer of Health for each patient. When a patient receiving opioid pharmacotherapy is admitted to hospital, continuation of treatment may occur while in hospital, provided it is safe to do so for up to one month.  Consultation with the patient’s authorised CPOP prescriber should be sought if dose adjustment is considered necessary.

It is important that the protocol attached is followed. This will reduce the risk to the patient of an overdose occurring.

Enquiries concerning these protocols or for general information on the CPOP, please contact (08) 9222 6812.


Professor Bryant Stokes
A/DIRECTOR GENERAL
DEPARTMENT OF HEALTH WA

Date of effect: 01 May 2015 to 01 May 2025

Policy Framework

Related documents

Supporting information